title: Characterisation of the xenogeneic immune response to microencapsulated fetal pig islet-like cell clusters transplanted into immunocompetent C57BL/6 mice.
abstract: Xenotransplantation of microencapsulated fetal pig islet-like cell clusters (FP ICCs) offers a potential cellular therapy for type 1 diabetes. Although microcapsules prevent direct contact of the host immune system with the xenografted tissue, poor graft survival is still an issue. This study aimed to characterise the nature of the host immune cells present on the engrafted microcapsules and effects on encapsulated FP ICCs that were transplanted into immunocompetent mice. Encapsulated FP ICCs were transplanted into the peritoneal cavity of C57BL/6 mice. Grafts retrieved at days 1, 3, 7, 14 and 21 post-transplantation were analysed for pericapsular fibrotic overgrowth (PFO), cell viability, intragraft porcine gene expression, macrophages, myofibroblasts and intraperitoneal murine cytokines. Graft function was assessed ex vivo by insulin secretion studies. Xenogeneic immune response to encapsulated FP ICCs was associated with enhanced intragraft mRNA expression of porcine antigens MIP-1α, IL-8, HMGB1 and HSP90 seen within the first two weeks post-transplantation. This was associated with the recruitment of host macrophages, infiltration of myofibroblasts and collagen deposition leading to PFO which was evident from day 7 post-transplantation. This was accompanied by a decrease in cell viability and loss of FP ICC architecture. The only pro-inflammatory cytokine detected in the murine peritoneal flushing was TNF-α with levels peaking at day 7 post transplantation. This correlated with the onset of PFO at day 7 implying activated macrophages as its source. The anti-inflammatory cytokines detected were IL-5 and IL-4 with levels peaking at days 1 and 7, respectively. Porcine C-peptide was undetectable at all time points post-transplantation. PFO was absent and murine intraperitoneal cytokines were undetectable when empty microcapsules were transplanted. In conclusion, this study demonstrated that the macrophages are direct effectors of the xenogeneic immune response to encapsulated FP ICCs leading to PFO mediated by a combination of both pro- and anti-inflammatory cytokines.
authors.affiliation: Diabetes Transplant Unit, Prince of Wales Hospital, School of Medical Sciences, University of New South Wales, Randwick, New South Wales, Australia.
authors.forename: Vijayaganapathy
authors.initials: V
authors.lastname: Vaithilingam
authors.forename: Cherry
authors.initials: C
authors.lastname: Fung
authors.forename: Sabina
authors.initials: S
authors.lastname: Ratnapala
authors.forename: Jayne
authors.initials: J
authors.lastname: Foster
authors.forename: Vijesh
authors.initials: V
authors.lastname: Vaghjiani
authors.forename: Ursula
authors.initials: U
authors.lastname: Manuelpillai
authors.forename: Bernard E
authors.initials: BE
authors.lastname: Tuch
mesh_terms: D000464:Alginates / Q000737:chemistry; D000818:Animals; D000941:Antigens / Q000276:immunology*; D015415:Biomarkers / Q000378:metabolism; D002465:Cell Movement; D016207:Cytokines / Q000096:biosynthesis / Q000276:immunology; D005333:Fetus; D020723:Glucuronic Acid / Q000737:chemistry; D006084:Graft Rejection / Q000276:immunology* / Q000473:pathology; D006603:Hexuronic Acids / Q000737:chemistry; D007121:Immunocompetence; D007328:Insulin / Q000378:metabolism; D000078790:Insulin Secretion; D007515:Islets of Langerhans / Q000166:cytology / Q000276:immunology*; D016381:Islets of Langerhans Transplantation / Q000379:methods*; D008264:Macrophages / Q000166:cytology / Q000276:immunology*; D051379:Mice; D058628:Myofibroblasts / Q000166:cytology / Q000276:immunology; D010529:Peritoneal Cavity; D013552:Swine; D014183:Transplantation, Heterologous; D016042:Transplantation, Heterotopic
chemical_list: D000464:Alginates; D000941:Antigens; D015415:Biomarkers; D016207:Cytokines; D006603:Hexuronic Acids; D007328:Insulin; D020723:Glucuronic Acid
references.citation: J Immunol. 1997 Jun 15;158(12):5658-67
references.pmid: 9190914
references.citation: Diabetes. 2003 Jan;52(1):69-75
references.pmid: 12502495
references.citation: Int Immunol. 2000 Nov;12(11):1539-46
references.pmid: 11058573
references.citation: J Microencapsul. 2011;28(6):499-507
references.pmid: 21827357
references.citation: Rev Diabet Stud. 2010 Spring;7(1):62-73
references.pmid: 20703439
references.citation: J Exp Med. 1986 Mar 1;163(3):632-43
references.pmid: 3512757
references.citation: Xenotransplantation. 2006 Nov;13(6):547-59
references.pmid: 17059582
references.citation: Transplantation. 2007 Jun 15;83(11):1440-8
references.pmid: 17565317
references.citation: Transplantation. 2005 Sep 27;80(6):821-7
references.pmid: 16210971
references.citation: Xenotransplantation. 2003 May;10(3):240-51
references.pmid: 12694544
references.citation: Xenotransplantation. 2007 Mar;14(2):157-61
references.pmid: 17381690
references.citation: Transplantation. 2000 Mar 27;69(6):1084-90
references.pmid: 10762211
references.citation: J Clin Invest. 1996 May 1;97(9):2119-29
references.pmid: 8621802
references.citation: J Clin Invest. 1996 Sep 15;98(6):1417-22
references.pmid: 8823307
references.citation: Xenotransplantation. 2007 Jan;14(1):74-82
references.pmid: 17214707
references.citation: Diabetes. 1998 Mar;47(3):316-23
references.pmid: 9519734
references.citation: Endocrinology. 2001 May;142(5):2115-22
references.pmid: 11316779
references.citation: J Mol Med (Berl). 1999 Jan;77(1):115-7
references.pmid: 9930942
references.citation: Xenotransplantation. 2004 Nov;11(6):525-30
references.pmid: 15479462
references.citation: Transplantation. 1990 Feb;49(2):396-404
references.pmid: 1968298
references.citation: Diabetologia. 1992 Mar;35(3):231-7
references.pmid: 1563581
references.citation: Cell Transplant. 2004;13(5):525-34
references.pmid: 15565865
references.citation: Endocrinology. 2001 Oct;142(10):4314-9
references.pmid: 11564690
references.citation: Diabetes. 2002 Jan;51(1):79-86
references.pmid: 11756326
references.citation: Proc Natl Acad Sci U S A. 1999 May 11;96(10):5645-50
references.pmid: 10318938
references.citation: Xenotransplantation. 1998 Aug;5(3):222-5
references.pmid: 9741461
references.citation: Transplantation. 1999 Apr 15;67(7):963-71
references.pmid: 10221479
references.citation: J Immunol. 1995 Mar 1;154(5):2470-82
references.pmid: 7868913
references.citation: Xenotransplantation. 2004 Sep;11(5):426-35
references.pmid: 15303979
references.citation: J Mol Med (Berl). 1999 Jan;77(1):215-8
references.pmid: 9930966
references.citation: Diabetologia. 1991 Jun;34(6):379-86
references.pmid: 1884897
references.citation: Transplantation. 2002 Mar 15;73(5):714-22
references.pmid: 11907416
references.citation: Transpl Immunol. 1997 Dec;5(4):307-14
references.pmid: 9504153
references.citation: Cell Transplant. 2001;10(3):285-93
references.pmid: 11437074
references.citation: Transplantation. 1996 Dec 27;62(12):1920-7
references.pmid: 8990388
references.citation: Transplantation. 1999 Apr 27;67(8):1105-11
references.pmid: 10232559
references.citation: Am J Transplant. 2004 Dec;4(12):1991-2000
references.pmid: 15575901
references.citation: J Biomed Mater Res. 2001 Dec 5;57(3):374-83
references.pmid: 11523032
references.citation: Xenotransplantation. 2003 Mar;10(2):164-77
references.pmid: 12588649
references.citation: Lancet. 1994 Nov 19;344(8934):1402-4
references.pmid: 7968077
references.citation: Transplantation. 2001 Jun 15;71(11):1671-7
references.pmid: 11435981
references.citation: J Clin Endocrinol Metab. 2003 Jun;88(6):2753-9
references.pmid: 12788884